2.13p-0.10 (-4.50%)28 Mar 2024, 16:30
Jump to:
Immupharma PLC Fundamentals
Company Name | Immupharma PLC | Last Updated | 2024-03-28 |
---|---|---|---|
Industry | Biotechnology | Sector | Healthcare |
Shares in Issue | 416.437 m | Market Cap | £8.67 m |
PE Ratio | 0.00 | Dividend per Share | 0 |
Dividend Yield | 0 | Dividend Cover | 0 |
EPS | -£0.01 | EPS Growth (%) | 0 |
PEG | 0 | DPS Growth (%) | 0 |
Debt Ratio | 0 | Debt Equity Ratio | 0 |
Asset Equity Ratio | 1.8928 | Cash Equity Ratio | 0.1212 |
Quick Ratio | 0.5909 | Current Ratio | 1.17 |
Price To Book Value | 5.2247 | ROCE | 0 |
Immupharma PLC Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|
Immupharma PLC Company Financials
Assets | 2022 | 2021 |
---|---|---|
Tangible Assets | £389,720.00 | £352,996.00 |
Intangible Assets | £473,892.00 | £477,553.00 |
Investments | £688,350.00 | £1.21 m |
Total Fixed Assets | £1.64 m | £2.65 m |
Stocks | 0 | 0 |
Debtors | £649,401.00 | £373,253.00 |
Cash & Equivalents | £667,813.00 | £1.65 m |
Other Assets | £83,788.00 | £612,997.00 |
Total Assets | £3.97 m | £6.00 m |
Liabilities | 2022 | 2021 |
---|---|---|
Creditors within 1 year | £1.45 m | £1.58 m |
Creditors after 1 year | 0 | 0 |
Other Liabilities | 0 | 0 |
Total Liabilities | £1.45 m | £1.58 m |
Net assets | £2.52 m | £4.41 m |
Equity | 2022 | 2021 |
---|---|---|
Called up share capital | £28.98 m | £28.50 m |
Share Premium | £28.79 m | £27.24 m |
Profit / Loss | -£4.46 m | -£8.94 m |
Other Equity | £2.52 m | £4.41 m |
Preference & Minorities | 0 | 0 |
Total Capital Employed | £2.52 m | £4.41 m |
Ratios | 2022 | 2021 |
---|---|---|
Debt Ratio | 0 | 0 |
Debt-to-Equity | 0 | 0 |
Assets / Equity | 1.8928 | 1.8928 |
Cash / Equity | 0.1212 | 0.1212 |
EPS | -£0.01 | -£0.02 |
Cash Flow | 2022 | 2021 |
---|---|---|
Cash from operating activities | -£2.35 m | -£4.83 m |
Cashflow before financing | -£799,335.00 | -£4.13 m |
Increase in Cash | -£876,759.00 | -£4.18 m |
Income | 2022 | 2021 |
---|---|---|
Turnover | 0 | £118,350.00 |
Cost of sales | 0 | 0 |
Gross Profit | 0 | 0 |
Operating Profit | -£3.03 m | -£6.59 m |
Pre-Tax profit | -£4.46 m | -£8.94 m |
Immupharma PLC Company Background
Sector | Healthcare |
---|---|
Activities | ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease. |
Latest Interim Date | 31 Aug 2023 |
Latest Fiscal Year End Date | 11 May 2023 |
Immupharma PLC Directors
Appointed | Name | Position |
---|---|---|
2021-07-30 | Dr. Franco Di Muzio | Non-Executive Director |
2006-03-31 | Mr. Douglas Gordon James Paterson | Non-Executive Director |
2024-03-19 | Mr. Timothy Paul McCarthy | Executive Director,Chairman and Chief Executive Officer |
2021-07-30 | Mr. Dimitri Dimitriou | Executive Director,Chief Executive Officer |
2021-05-24 | Dr. Robert Henri Zimmer | Executive Director,President and Chief Scientific Officer |
2016-05-05 | Mr. Richard Leonard Warr | Executive Director,Chairman |
2016-05-05 | Dr. Ajay Agrawal | Non-Executive Director |
2011-08-09 | Mr. Paddy Hugh Walker-Taylor FCA,MCT | Executive Director,Chief Financial Officer |
2006-03-31 | Mr. Anthony Johnson B.Pharm,MSc | Non-Executive Director |
2023-08-11 | Dr. Sanjeev Pandya | Non-Executive Director,Senior Independent Director |
2021-07-30 | Dr. Stephane Robert George Mery | Non-Executive Director |
2024-03-19 | Mr. Timothy Gary Franklin | Executive Director,Chief Operating Officer |
2023-09-07 | Ms. Lisa Baderoon | Non-Executive Director |
Immupharma PLC Contact Details
Company Name | ImmuPharma PLC |
---|---|
Address | One Bartholomew Close, London, EC1A 7BL |
Telephone | +44 2071524080 |
Website | https://www.immupharma.co.uk |
Immupharma PLC Advisors
Stockbroker | Bryan, Garnier & Co Limited |
---|---|
Phone | +44 2073322500 |
Nominated Adviser | Northland Capital Partners |
---|---|
Phone | +44 2038616625 |
Fax | +44 2076005975 |
Stockbroker | Northland Capital Partners |
---|---|
Phone | +44 2038616625 |
Fax | +44 2076005975 |
Registrar | Computershare Investor Services PLC |
---|---|
Phone | +44 3707020003 |
Fax | +44 3707036101 |
Auditor | Nexia Smith & Williamson |
---|---|
Phone | +44 2071314000 |
Fax | +44 2071314001 |
Solicitor | Bircham Dyson Bell |
---|---|
Phone | +44 2072277000 |
Fax | +44 2072223480 |
Bank | Royal Bank of Scotland PLC |
---|
Auditor | Nexia Smith & Williamson Audit Limited |
---|
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
Company | Price | % Chg |
---|---|---|
Jd Sports Fashion PLC | 134.50 | 15.65 |
Ao World PLC | 100.80 | 12.19 |
Spirent Communications PLC | 198.00 | 10.61 |
Hipgnosis Songs Fund Limited | 69.04 | 8.39 |
Diversified Energy Company PLC | 948.00 | 6.22 |
Elementis PLC | 146.50 | 4.49 |
Fallers
Company | Price | % Chg |
---|---|---|
Ithaca Energy PLC | 133.00 | -8.65 |
M&G PLC | 220.39 | -6.14 |
Carnival PLC | 1,169.50 | -5.42 |
Smith & Nephew PLC | 1,005.83 | -3.61 |
Moneysupermarket.Com Group PLC | 219.80 | -3.43 |
Balanced Commercial Property Trust Limited | 81.40 | -3.10 |